CADDS

Other names
Types
Causes
Common symptoms and signs
Diagnostic tests
Non-pharmacological treatments (therapies and other supports)
Drug treatments
Dietary molecular supplements
Immunity-booster / Regenerative / Stem-cell” drugs
Surgeries (procedure and why they are done)
Preventions
When to see doctors
Foods to favor and to avoid
Frequently asked questions (FAQs)

CADDS stands for Contiguous ABCD1/DXS1357E deletion syndrome. It is a very rare, inherited condition caused by losing (deleting) two neighboring genes on the X chromosome: ABCD1 and DXS1357E/BAP31. Because these genes are important for breaking down certain fats and for healthy cell-membrane traffic inside the endoplasmic reticulum, their combined loss disrupts many organs from birth. Babies with CADDS often have poor growth before and after birth, very floppy muscles (low tone), severe developmental delay, feeding problems, liver cholestasis (bile cannot flow well), very high very-long-chain fatty acids (VLCFAs) in blood (a marker of peroxisome problems), seizures, vision and hearing problems, and brain changes such as delayed myelination and enlarged ventricles. Sadly, the illness can be life-threatening in early infancy. GARD Information Center+1

CADDS (also called contiguous ABCD1/DXS1357E deletion syndrome / “Zellweger-like contiguous gene deletion syndrome”). CADDS is an extremely rare, X-linked neurometabolic disorder marked by severe growth restriction before birth, profound low muscle tone in newborns, global developmental delay, high very-long-chain fatty acids (VLCFAs), cholestasis with risk of neonatal liver failure, eye problems (cataract), hearing loss, seizures, and delayed brain myelination/ventriculomegaly. Day-to-day treatment is largely supportive and multidisciplinary, and decisions must be individualized by specialists experienced with leukodystrophies and metabolic liver disease. GARD Information Center+2NCBI+2

CADDS is caused by a missing piece on the X-chromosome that removes the ABCD1 gene (and nearby genes). Without ABCD1, the body cannot move certain very long fats (VLCFAs) into peroxisomes for breakdown. These fats build up and injure the brain’s white matter and adrenal glands. In CADDS, other nearby gene losses add severe problems: poor growth in the womb, very weak muscles at birth, feeding trouble, jaundice and cholestasis that can progress to liver failure, seizures, eye problems (cataracts), and hearing loss. Many babies become very sick early. Care focuses on supporting breathing, feeding, preventing low blood sugar, managing seizures, protecting vision and hearing, and supporting the liver. GARD Information Center+2MedlinePlus+2

Because ABCD1 is within the deletion, aspects of care overlap with X-linked adrenoleukodystrophy (X-ALD) (e.g., adrenal surveillance, VLCFA issues). A few advanced options (e.g., elivaldogene autotemcel / SKYSONA gene therapy and hematopoietic stem-cell transplant) apply only to carefully selected boys with early cerebral ALD (CALD) and are not universally applicable to infants with multisystem CADDS; any discussion must occur at a CALD-expert center. NCBI+1

Researchers first described CADDS as a contiguous gene deletion syndrome that behaves differently from classic X-linked adrenoleukodystrophy (X-ALD). Although ABCD1 mutations alone cause X-ALD, the combined deletion with BAP31 (DXS1357E) creates a broader, more severe, “Zellweger-like” picture with multiorgan disease and very early onset. PubMed

Recent reports continue to expand the medical picture, noting that some individuals may also show lung disease (interstitial changes) and pancreatic exocrine insufficiency, underlining how multi-systemic CADDS can be. Wiley Online Library

Other names

Contiguous ABCD1/DXS1357E deletion syndrome
ABCD1–BAP31 contiguous deletion syndrome
ABCD1/BAP31 microdeletion syndrome
A rare disease listing may simply say “CADDS” (the acronym) on medical databases. GARD Information Center+2Orpha+2

Types

There are no universally accepted clinical subtypes of CADDS at this time. Doctors sometimes group cases by severity or main organ involvement (for example, liver-predominant early failure vs. neurodevelopmental-predominant presentations) or by size of the Xq28 deletion and which nearby genes are included. But these are descriptive groupings rather than formal types. The condition remains defined by the combined loss of ABCD1 and BAP31 (DXS1357E) and its recognizable, severe, early-onset pattern. PubMed+1

Causes

Because CADDS is genetic, the “cause” is the X-chromosome deletion that removes both ABCD1 and BAP31. Below are 20 simple, mechanism-level explanations of how that deletion leads to the illness you see:

Loss of ABCD1 → reduced transport of VLCFA into peroxisomes, so these fats build up in tissues and blood. PubMed
Peroxisomal β-oxidation failure → cells cannot break down VLCFA efficiently, harming liver, brain, and adrenal tissues. GARD Information Center
Loss of BAP31 (DXS1357E) → disturbed endoplasmic reticulum (ER) protein trafficking and stress signaling, worsening multi-organ disease. PubMed
Combined deletion effect → the ABCD1 + BAP31 loss produces a broader, more severe phenotype than ABCD1 alone (different from “classic” X-ALD). PubMed
Toxic VLCFA accumulation → damages myelin-forming cells and impairs brain myelination, leading to delayed white-matter development. GARD Information Center
Neuronal dysfunction from ER stress and lipid toxicity → hypotonia, seizures, and developmental delay. GARD Information Center
Liver cholestasis from cellular injury → poor bile flow, fat-soluble vitamin deficiency, and risk of hepatic failure. GARD Information Center
Mitochondrial secondary stress due to lipid overload → energy handling becomes inefficient, worsening fatigue and organ failure (inferred from peroxisomal disease biology). GARD Information Center
Oxidative stress triggered by VLCFA excess and ER dysfunction → further tissue damage over time (general peroxisomal pathophysiology). GARD Information Center
Abnormal brain structure (ventriculomegaly, delayed myelination) → reflects disrupted development from in-utero onward. GARD Information Center
Feeding difficulty and failure to thrive → both a symptom and driver of worsening malnutrition and weakness. GARD Information Center
Endocrine vulnerability due to ABCD1 loss (known in X-ALD) → potential adrenal involvement, although CADDS is dominated by multi-system infant disease. PubMed
Immune/inflammatory activation secondary to tissue injury → can compound liver and brain problems (general mechanism in cholestasis and leukodystrophies). GARD Information Center
Hearing loss from neural and sensory organ involvement → limits language development and social engagement. GARD Information Center
Vision loss (including cataracts/retinal issues) → reflects ocular tissue vulnerability to lipid and ER stress. GARD Information Center
Seizure networks aggravated by white-matter injury → further delays development and increases care needs. GARD Information Center
Respiratory complications in some reports (interstitial lung disease) → impaired gas exchange and recurrent illness. Wiley Online Library
Pancreatic exocrine insufficiency in some reports → poor digestion and nutrient absorption. Wiley Online Library
Genetic dosage (size of deletion and neighboring genes) → may modify severity and which organs are most affected. PubMed
X-linked inheritance → typically affects males more severely; female carriers may have variable features depending on X-inactivation (general X-linked principle). PubMed

Common symptoms and signs

Before-birth poor growth (IUGR) — baby grows too slowly in the womb. GARD Information Center+1
Poor weight gain after birth (failure to thrive) — cannot gain enough weight despite feeds. GARD Information Center
Very low muscle tone (floppiness) — feels “limp” when held; delays in head control. GARD Information Center
Severe developmental delay — slow or absent milestones (rolling, sitting, speech). GARD Information Center
Feeding problems — weak suck, frequent spit-ups, or choking with feeds. GARD Information Center
Liver cholestasis — yellow skin/eyes (jaundice), pale stools, dark urine. GARD Information Center
Risk of liver failure — worsening jaundice, swelling, bleeding problems. GARD Information Center
Seizures — episodes of stiffening, jerking, staring, or loss of awareness. GARD Information Center
Vision problems — poor visual tracking, cataracts, or blindness in severe cases. GARD Information Center
Hearing loss — reduced response to sounds; may need hearing support. GARD Information Center
Abnormal brain imaging — delayed myelination and enlarged fluid spaces (ventricles). GARD Information Center
Breathing issues — sometimes related to lung disease or weak muscles. Wiley Online Library
Recurrent infections or hospital stays — due to feeding tubes, poor nutrition, or aspiration. (Clinical course described in rare disease profiles.) GARD Information Center
Endocrine-related concerns — adrenal vulnerability is known in ABCD1 disorders, though CADDS course is dominated by infant multi-organ illness. PubMed
Early mortality risk — many babies become critically ill in the first months of life. GARD Information Center

Diagnostic tests

A) Physical exam (bedside observations)

Growth assessment — weight, length, and head size track poor growth from birth; failure to thrive raises concern. GARD Information Center
Neurologic tone and reflex check — documents generalized hypotonia, weak reflexes, and delayed milestones. GARD Information Center
Liver exam — enlarged liver, jaundice, and signs of cholestasis (pale stools) suggest hepatic involvement. GARD Information Center
Vision and hearing screen — bedside checks for tracking and startle to sound to catch early sensory loss. GARD Information Center

B) Manual/functional tests (simple clinical tools)

Developmental screening scales (e.g., Bayley style tools) — quantify motor/speech delay to guide therapies. (Standard pediatric practice for global delay in rare diseases.) GARD Information Center
Bedside swallow evaluation — identifies aspiration risk and need for modified feeds or tube support. (Common evaluation in infants with hypotonia/failure to thrive.) GARD Information Center
Audiology behavioral testing (age-appropriate) — helps confirm suspected hearing loss from bedside screens. GARD Information Center
Ophthalmologic slit-lamp exam — manual eye exam for cataracts/retinal issues contributing to poor vision. GARD Information Center

C) Lab and pathological tests

Plasma very-long-chain fatty acids (VLCFAs) — typically elevated and a major biochemical clue to peroxisomal dysfunction in CADDS. GARD Information Center
Liver function tests and cholestasis panel — bilirubin (direct), gamma-GT, transaminases to gauge liver injury. GARD Information Center
Fat-soluble vitamin levels (A, D, E, K) — often low in cholestasis; guide supplementation. GARD Information Center
Endocrine testing (e.g., cortisol/ACTH) — screens for adrenal involvement known in ABCD1-related disease. PubMed
Pancreatic stool elastase (if poor weight gain/steatorrhea) — checks for exocrine pancreatic insufficiency as reported in some CADDS cases. Wiley Online Library
Metabolic workup (acylcarnitines, peroxisomal panel) — rules out or supports other inborn errors alongside VLCFAs. (Standard peroxisomal disease evaluation.) GARD Information Center

D) Electrodiagnostic tests

EEG (electroencephalogram) — detects seizures and background slowing consistent with severe encephalopathy. (Seizures common in CADDS.) GARD Information Center
Brainstem auditory evoked responses (BAER) — objective measure of hearing pathway function when behavioral tests are hard in infants. (Useful with suspected sensorineural deafness.) GARD Information Center

E) Imaging tests

Brain MRI — often shows delayed myelination and ventriculomegaly, matching the neurologic picture. GARD Information Center
Liver ultrasound — assesses liver size, bile ducts, and secondary complications of cholestasis. GARD Information Center
Chest imaging (X-ray/HRCT as needed) — evaluates interstitial lung disease if there are breathing symptoms. Wiley Online Library
Genomic testing — chromosomal microarray or exome/genome sequencing with deletion analysis to confirm the Xq28 contiguous deletion involving ABCD1 and BAP31 (DXS1357E); this is the definitive diagnosis. PubMed

Non-pharmacological treatments (therapies and other supports)

Neonatal intensive supportive care. Stabilize breathing, temperature, blood glucose, and treat infections quickly. Gentle handling and warm environment help because sick infants with VLCFA and cholestasis are fragile. Early transfer to a tertiary NICU with neurometabolic and liver expertise is ideal. GARD Information Center+1
Structured feeding support and swallowing therapy. Many babies have poor suck and swallow. A speech-language therapist can assess aspiration risk and advise pacing, nipple changes, and thickening. If unsafe, temporary nasogastric feeds are used; if long-term, a gastrostomy tube (G-tube) can provide safe nutrition and medications. GARD Information Center
Targeted neonatal nutrition. Dietitians aim for adequate calories, protein, fat-soluble vitamins (A, D, E, K), and careful fat choices (see supplements below). In cholestasis, fat-soluble vitamin absorption is poor, so monitored replacement is essential. GARD Information Center
Physiotherapy for hypotonia. Gentle range-of-motion work, positioning, and developmental handling reduce contractures, improve head control, and aid comfort. Programs are individualized and progress slowly. GARD Information Center
Occupational therapy. Focus on positioning for feeding/vision, hand-to-mouth practice, and caregiver training to reduce stress and promote bonding and comfort. GARD Information Center
Early intervention (developmental services). Even in severe disease, consistent sensory stimulation, parent coaching, and routine-based therapy can preserve abilities and quality of life. GARD Information Center
Seizure safety education and rescue plans. Families learn seizure first-aid, triggers, and when to seek urgent care. Electroencephalography guides drug choices (see drug section). GARD Information Center
Hearing rehabilitation. For severe sensorineural hearing loss, early hearing aids and evaluation at a cochlear implant program (often before age 1–2 if criteria met) improve access to sound and communication outcomes. AAO-HNS+2PMC+2
Vision care. Pediatric ophthalmology monitors for cataract; early surgery for visually significant cataracts can prevent amblyopia and improve visual input for development. NCBI+1
Liver-failure pathway readiness. Teams follow standardized pediatric acute liver failure (PALF) protocols (frequent INR, ammonia, glucose, electrolytes) and prepare for urgent transplant evaluation if deterioration occurs. AASLD
Infection prevention & vaccination on schedule. Fragile infants with liver dysfunction are infection-prone; up-to-date immunizations, careful hand hygiene, and prompt evaluation of fever are critical. AASLD
Endocrine surveillance for adrenal insufficiency. Because ABCD1 loss predisposes to adrenal failure, periodic morning cortisol/ACTH and stress-dose plans are essential—even in infancy. NCBI
Genetic counseling for the family. Clarifies X-linked inheritance, carrier testing for females, and options for future pregnancies; also prompts screening of at-risk relatives for X-ALD. NCBI+1
Newborn screening linkages (where available). Some regions screen for X-ALD; positive results fast-track endocrine and neuroimaging surveillance and referral to transplant/gene therapy centers for eligible CALD cases. PMC+1
Palliative care integration. Early palliative care relieves symptoms (pain, irritability, pruritus) and supports family decision-making given the high risk of early mortality from liver failure and neurologic disease. GARD Information Center
Care coordination across specialties. Regular case conferences among neonatology, hepatology, neurology, endocrinology, ophthalmology, audiology, nutrition, and genetics reduce conflicting plans and hospitalizations. GARD Information Center
Sunlight/temperature protection. Maintain warmth (especially during procedures/transport) because sick neonates decompensate with cold stress; this is routine NICU best practice. AASLD
Skin care and pressure-injury prevention. Hypotonia and edema increase breakdown risk; frequent turning and barrier creams help. GARD Information Center
Family training for home care. G-tube care, medication administration, seizure plans, vitamin dosing, and signs of adrenal crisis or liver failure empower safe home transitions. GARD Information Center
Community and rare-disease networks. Leukodystrophy foundations and GARD contacts help locate experience, trials, and peer support. GARD Information Center

Drug treatments

Important: No medicine is FDA-approved to “treat CADDS itself.” The drugs below are used to treat complications commonly seen in CADDS (adrenal insufficiency, neonatal seizures, cholestasis, nutrition deficits), drawing on FDA labels, neonatal/child practice, or related X-ALD care. Always dose by weight, age, organ function, and specialist guidance.

Hydrocortisone (CORTEF®) — for suspected/confirmed primary adrenal insufficiency or stress-dosing during acute illness. Class: glucocorticoid. Typical dosing (maintenance infants): individualized; stress dosing for illness per endocrine plan. Purpose: replaces cortisol to prevent shock/hypoglycemia. Mechanism: binds glucocorticoid receptor → supports glucose, vascular tone, and stress response. Side effects: infection risk, hypertension, hyperglycemia, growth impact; taper after prolonged use. FDAaccessdata+1
Fludrocortisone acetate — add for mineralocorticoid replacement when aldosterone is low. Class: mineralocorticoid. Dose: tiny daily dose per endocrinology with salt supplementation. Purpose: maintains sodium/volume. Mechanism: kidney Na⁺ retention/K⁺ loss. Side effects: hypertension, edema, hypokalemia—monitor closely. NCTR CRS+1
Levetiracetam (KEPPRA® / KEPPRA XR®) — common first-line antiseizure in infants beyond the immediate neonatal period. Class: antiepileptic. Dose: weight-based, divided twice daily. Purpose: reduce seizures. Mechanism: binds SV2A to modulate synaptic release. Side effects: somnolence, irritability; rare behavioral symptoms—monitor. FDAaccessdata+1
Phenobarbital / Phenobarbital sodium (SEZABY® for neonatal use) — neonatal seizures first-line in many NICUs. Class: barbiturate antiepileptic. Dose: loading/maintenance IV or oral per protocols. Purpose: seizure control in term/preterm neonates. Mechanism: GABA-A modulation. Side effects: sedation, respiratory depression; careful monitoring. FDAaccessdata
Ursodiol (URSO® / ACTIGALL®) — used for cholestasis in infants/children (off-label in some situations; data mixed). Class: bile acid. Dose: commonly 10–20 mg/kg/day divided; specialist adjusts. Purpose: improve bile flow, pruritus, fat-soluble vitamin absorption. Mechanism: hydrophilic bile acid replaces toxic bile acids. Side effects: usually mild GI; efficacy in neonates is debated. FDAaccessdata+2FDAaccessdata+2
Vitamin K (phytonadione) — for coagulopathy in cholestasis. Class: vitamin. Dose: per INR/status; oral often poorly absorbed in cholestasis → parenteral may be used. Purpose: prevent/stop bleeding. Mechanism: restores γ-carboxylation of clotting factors. Side effects: injection reactions. (Label references within hospital protocols; evidence base from cholestasis practice.) GARD Information Center
Fat-soluble vitamins A, D, E — deficiency prevention in cholestasis (water-miscible preparations). Purpose: prevent rickets, neuropathy/retinopathy, poor growth. Mechanism: replaces deficient vitamins when bile-dependent absorption is impaired. Side effects: hypervitaminosis risk—dose by levels. GARD Information Center
Elivaldogene autotemcel (SKYSONA®) — gene therapy for early, active CALD (boys, 4–17 y) without a suitable HSCT donor; not for multisystem neonatal CADDS but relevant to ABCD1-related cerebral disease spectrum. Class: autologous CD34+ cells transduced ex vivo (Lenti-D). Dose: single IV infusion after myeloablation. Purpose: slow neurologic decline in CALD. Mechanism: restores ABCD1 in autologous HSCs → microglial engraftment. Side effects: boxed warning for hematologic malignancy; requires long-term oncology monitoring. U.S. Food and Drug Administration+3U.S. Food and Drug Administration+3U.S. Food and Drug Administration+3
Acetaminophen (careful dosing) — for fever/pain to reduce metabolic stress; avoid overdose and consider liver status. Class: analgesic/antipyretic. Mechanism: central COX modulation. Side effects: hepatotoxicity at high doses—strict dosing in liver disease. AASLD
Broad-spectrum antibiotics (per culture/clinical judgment). Neonates with liver failure are high-risk for sepsis; early empiric therapy when ill is standard PALF practice. Side effects: diarrhea, resistance; de-escalate with cultures. AASLD
Proton-pump inhibitor/H2 blocker (if stress gastritis risk with steroids/critical illness). Purpose: protect mucosa; Caution: minimize duration. FDAaccessdata
Levo-carnitine (CARNITOR®) — for documented carnitine deficiency or certain inborn errors with secondary deficiency; may be considered if levels low and cholestasis/seizure polypharmacy present. Class: nutrient. Mechanism: shuttles long-chain fatty acids into mitochondria. Side effects: GI upset, fishy odor. FDAaccessdata
Vitamin D (calciferol) with calcium — rickets prevention in cholestasis/immobility; dose by levels. GARD Information Center
Cholestyramine (select cases of pruritus) — binds bile acids in gut; watch fat-soluble vitamin depletion and drug interactions. GARD Information Center
Rifampin (refractory cholestatic itch, specialist-guided) — induces hepatic enzymes and alters pruritogen metabolism; monitor liver tests. AASLD
Naloxone/naltrexone (specialist-guided) — opioid-antagonist strategy for pruritus pathways; neonatal data limited. AASLD
Medium-chain triglyceride (MCT)-based formulas (technically nutrition, not “drug”) — improve caloric delivery in cholestasis because MCTs are absorbed more easily; monitor growth and essential fatty acids. GARD Information Center
Rescue benzodiazepine (e.g., midazolam in ICU) for status epilepticus per pediatric protocols; monitor respiration. AASLD
Electrolyte/glucose correction protocols (IV dextrose, sodium management) — prevent seizures/arrhythmias in liver failure. AASLD
Vaccines (per schedule; avoid live vaccines only if contraindicated by immune status/therapy) — protect against severe infections. Coordinate timing around high-dose steroids or transplant. AASLD

Dietary molecular supplements

Note: Supplements should be used only under specialist guidance with lab monitoring—especially in cholestasis and liver failure.

MCT oil / MCT-rich formulas. What it does: supplies energy that is easier to absorb without bile. How it works: MCTs enter portal vein directly and do not need micelles, easing fat absorption during cholestasis. Use: blend into feeds per dietitian; monitor growth and essential long-chain fatty acids. GARD Information Center
Vitamin A (water-miscible). Function: vision/epithelial health. Mechanism: replaces deficient retinol when bile-dependent absorption fails. Monitoring: levels to avoid toxicity. GARD Information Center
Vitamin D (D2/D3, sometimes calcidiol/calcitriol). Function: bone mineralization/immune modulation. Mechanism: restores low 25-OH D in cholestasis; activated forms used if severe liver dysfunction. GARD Information Center
Vitamin E (tocopherol, water-soluble form). Function: antioxidant protection of neuronal membranes. Mechanism: corrects low α-tocopherol common in cholestasis to reduce neuropathy/hemolysis risk. GARD Information Center
Vitamin K (phytonadione). Function: clotting factor activation; Mechanism: cofactor for γ-carboxylation in liver; parenteral may be needed in cholestasis. GARD Information Center
Essential fatty acids (linoleic/alpha-linolenic). Function: prevent EFAD when using MCTs and low long-chain fats. Mechanism: small LCFA supplements with monitoring. GARD Information Center
Zinc. Function: supports growth and immune function; losses can be high with cholestasis/diarrhea. Mechanism: cofactor in numerous enzymes. Monitor copper balance. GARD Information Center
Selenium. Function: antioxidant enzyme (glutathione peroxidase). Mechanism: may be low with parenteral nutrition or cholestasis; correct deficiency only. GARD Information Center
Carnitine (levocarnitine). Function: correct deficiency that worsens fatigue and impairs fatty-acid handling. Mechanism: shuttles fatty acids into mitochondria; lab-guided dosing. FDAaccessdata
Omega-3 (DHA/EPA) with caution. Function: membrane support/anti-inflammatory effects; Mechanism: incorporates into neuronal membranes; ensure bleeding risk and liver status are reviewed first. GARD Information Center

Immunity-booster / Regenerative / Stem-cell” drugs

There is no proven “immunity booster” drug for CADDS. Two advanced, disease-spectrum options target ABCD1-related cerebral disease in carefully selected patients; the rest are supportive.

Elivaldogene autotemcel (SKYSONA®) — gene therapy for eligible boys (4–17 y) with early, active CALD without an HLA-matched donor. It can slow neurologic decline, but carries a boxed warning for hematologic malignancy and requires expert centers and long-term surveillance. Not intended for unstable neonates with multisystem CADDS. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2
Allogeneic hematopoietic stem-cell transplantation (HSCT) — a procedure, not a drug, but a key regenerative therapy for early CALD if done before major MRI progression. Requires matched donor and transplant center; risks include graft-versus-host disease and transplant-related mortality. (Listed here for context.) NCBI
Hydrocortisone (see above) — supports immune and stress responses in adrenal insufficiency; prevents life-threatening adrenal crisis during illness/surgery. FDAaccessdata
Fludrocortisone (see above) — restores mineralocorticoid function to stabilize blood pressure/volume when aldosterone is low. NCTR CRS
Fat-soluble vitamins (A, D, E, K). Correcting deficiencies is immune-supportive (e.g., vitamin D) and critical for neurologic/hematologic health in cholestasis. GARD Information Center
Levo-carnitine — replacement when objectively low may support energy metabolism; not an “immune booster” but can improve nutritional status. FDAaccessdata

Surgeries (procedure and why they are done)

Cataract extraction (pediatric). Why: visually significant cataracts block visual development. When: ideally within weeks for unilateral dense cataract; bilateral by ~8 weeks to reduce amblyopia risk. Goal: improve visual input for brain development. NCBI+1
Cochlear implant (in candidates after hearing-aid trial). Why: provide auditory input in severe-profound bilateral sensorineural hearing loss with limited benefit from amplification. Goal: language access and interaction. Cochlear+1
Gastrostomy tube (G-tube). Why: unsafe or ineffective oral feeding due to hypotonia/aspiration. Goal: secure nutrition, hydration, and medication delivery. GARD Information Center
Liver transplantation. Why: neonatal acute liver failure or end-stage cholestatic disease unresponsive to medical care. Goal: life-saving replacement of failing liver. (Candidacy depends on overall prognosis and neurologic status.) AASLD+1
Central venous access (e.g., for intensive care, parenteral nutrition, or transplant/gene-therapy workflows). Why: reliable delivery of therapies in fragile infants. AASLD

Preventions

Genetic counseling for family planning (X-linked inheritance; carrier testing for females). NCBI
Screen at-risk relatives for ABCD1 variants/X-ALD, especially male relatives. NCBI
Antenatal counseling in future pregnancies (options include prenatal or preimplantation genetic testing where legal and available). NCBI
Newborn screening connections (where implemented) so affected newborns enter endocrine/neuro monitoring early. PMC
Standard vaccines on time; protect from vaccine-preventable infections. AASLD
Early endocrine checks to prevent adrenal crisis (morning cortisol/ACTH, stress-dose plan). NCBI
Early eye and hearing evaluations to avoid missed windows for cataract surgery or cochlear implantation. NCBI+1
Nutrition surveillance (growth curves, vitamins A/D/E/K, essential fatty acids), especially in cholestasis. GARD Information Center
Infection precautions during high-risk periods (e.g., after steroids, invasive lines, or transplant). AASLD
Caregiver training and emergency plans (seizure rescue, adrenal crisis kit, when to call EMS). AASLD

When to see doctors

Immediately for poor feeding, repeated vomiting, fever, lethargy, fast breathing, seizures, new jaundice deepening, easy bruising/bleeding, swollen belly, or any cyanosis/apnea. These can signal adrenal crisis, liver failure, infection, or worsening seizures. AASLD
Urgently if there is sudden hearing or vision change, marked irritability, decreased arousal, or prolonged diarrhea. AASLD
Routinely for scheduled endocrine, neurology, hepatology, ophthalmology, audiology, nutrition, and genetics follow-up. GARD Information Center

Foods to favor and to avoid

Note: No CADDS-specific “curative” diet exists. If cholestasis is present, follow your liver team’s plan.

Eat more (as advised by dietitian):

MCT-based infant formula or MCT-enriched feeds for easier fat absorption. GARD Information Center
Protein-adequate feeds (formula/breastmilk fortification) to support growth. GARD Information Center
Water-miscible vitamins A, D, E, K as prescribed. GARD Information Center
Electrolyte-balanced fluids per plan to prevent dehydration. AASLD
Essential fatty-acid supplements in small, monitored amounts to prevent deficiency. GARD Information Center
Iron-appropriate feeds only if recommended (monitor ferritin). AASLD
Zinc-containing feeds if deficient. GARD Information Center
Low-lactose options if intolerance suspected. AASLD
Small, frequent feeds to limit fatigue/hypoglycemia. AASLD
Parenteral nutrition (when needed) to bridge severe cholestasis and growth failure under specialist care. AASLD

Avoid or limit (unless the team advises otherwise):

High-fat long-chain triglyceride loads in uncontrolled cholestasis (hard to absorb). GARD Information Center
Herbal/“liver cleanse” products (risk of toxicity). AASLD
Unregulated “immune boosters.” No proof in CADDS; may harm the liver. AASLD
Excessive vitamin A or D beyond monitored targets (toxicity risk). GARD Information Center
Grapefruit juice with certain medicines (interactions). AASLD
Honey in infants <1 year (botulism risk). AASLD
Unpasteurized dairy/juices (infection risk). AASLD
Raw/undercooked eggs or meats (infection). AASLD
High-sodium foods if on fludrocortisone with hypertension—follow BP checks. NCTR CRS
Large volumes of free water without electrolytes if hyponatremia risk—follow care plan. AASLD

Frequently asked questions (FAQs)

1) Is there a cure for CADDS?
No single curative drug exists. Care is supportive and complication-directed. Selected boys with early CALD may be candidates for HSCT or SKYSONA® gene therapy, but these are for a specific cerebral ALD phenotype, not for multisystem neonatal CADDS. NCBI+1

2) Can diet fix the VLCFA problem?
Diet alone cannot normalize VLCFAs in ABCD1 loss. MCT-based formulas help energy delivery when bile flow is poor; essential fatty acids must still be supplied carefully. NCBI

3) Why are fat-soluble vitamins so important?
Cholestasis blocks absorption of A, D, E, K; replacing them prevents bleeding, bone disease, and neurologic problems. GARD Information Center

4) Do all babies with CADDS need liver transplant?
No. Transplant is considered for acute liver failure or progressive end-stage disease after intensive medical management, balancing overall prognosis. AASLD+1

5) My baby has seizures—what is first-line?
Phenobarbital is commonly used in neonates; levetiracetam is used broadly beyond the immediate neonatal period. Choices depend on EEG, age, organ function, and side-effect profile. FDAaccessdata+1

6) Should we expect adrenal problems?
Yes, ABCD1 loss increases risk of primary adrenal insufficiency; regular endocrine testing and stress-dose hydrocortisone plans are vital. NCBI

7) Is cochlear implantation possible?
If severe-profound bilateral sensorineural hearing loss is confirmed and hearing aids give limited benefit, children—even infants—may qualify after evaluation at an implant center. PMC+1

8) When should cataracts be removed?
Visually significant congenital cataracts are removed early (often within weeks) to prevent amblyopia, guided by pediatric ophthalmology. NCBI

9) Are “immunity boosters” helpful?
There is no proven immunity-boosting drug for CADDS. Focus on vaccines, nutrition, vitamins (A/D/E/K) as prescribed, and prevention of infections. AASLD

10) What about Lorenzo’s oil or experimental diets?
These are not FDA-approved and have mixed evidence; do not start without a specialist metabolic team. NCBI

11) Will my child walk or talk?
Outcomes vary and can be poor due to severe brain and liver disease. Early therapy focuses on comfort, communication alternatives, and maximizing abilities. GARD Information Center

12) Can newborn screening help our family?
In regions where X-ALD is on the RUSP, newborn screening can identify affected infants earlier and prompt endocrine/MRI surveillance and referral for CALD therapies when appropriate. PMC

13) How often are labs and imaging needed?
In early disease, teams may monitor INR, bilirubin, ammonia, glucose, electrolytes, cortisol/ACTH, and obtain EEG/MRI as clinically indicated. Frequency depends on stability. AASLD

14) What support communities exist?
Leukodystrophy foundations, GARD, and hospital social work can connect families with resources and peer support. GARD Information Center

15) Where should we be treated?
Whenever possible, at a center of excellence with experience in leukodystrophies, pediatric liver failure, pediatric audiology/ophthalmology, and endocrine care. GARD Information Center

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.